Biosimilar User Fee Talks Begin With Industry Negotiating Amongst Itself
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA asks negotiators from the four industry groups to coordinate proposed changes as BsUFA renewal talks get underway.
You may also be interested in...
US FDA Might Face Funding Penalty For Missing User Fee Goals
Industry representatives support adding a provision to the user fee agreements that would withdraw some taxpayer funding if the agency does not meet its deliverables.
Biosimilar User Fee Agreement Offers FDA Funding Boost, Fee Structure Overhaul
BsUFA revenue amounts and fees will be separated from PDUFA and relative contribution of each fee type to the overall pot will change; user fee revenue target for program's first year is $45m.
Biosimilar User Fee Agreement Offers FDA Funding Boost, Fee Structure Overhaul
BsUFA revenue amounts and fees will be separated from PDUFA and relative contribution of each fee type to the overall pot will change; user fee revenue target for program's first year is $45m.